IM Cannabis (IMCC) Stock Price, News & Analysis

Company Overview

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

Key Stats

• Today's Range: $0.22 to $0.24
• 50-Day Range: $0.22 to $0.41
• 52-Week Range: $0.21 to $3.75
• Volume: 231,243 shs
• Average Volume: 720,727 shs
• Market Capitalization: $1.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

IM Cannabis Stock Analysis - MarketRank™

IM Cannabis scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

IM Cannabis has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

IM Cannabis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IM Cannabis is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IM Cannabis is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.65% of the float of IM Cannabis has been sold short.

Short Interest Ratio / Days to Cover

IM Cannabis has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IM Cannabis has recently increased by 271.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IM Cannabis does not currently pay a dividend.

Dividend Growth

IM Cannabis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.29

News Sentiment

IM Cannabis has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IM Cannabis this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IM Cannabis insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.91% of the stock of IM Cannabis is held by insiders.

Percentage Held by Institutions

7.68% of the stock of IM Cannabis is held by institutions.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 6/13/2026
• Next Earnings (Estimated): 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCC
• CIK: 1792030
• Web: www.imcannabis.com
• Phone: 972-54-433-1111
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.10 million
• Net Margins: -27.65%
• Pretax Margin: -27.91%
• Return on Equity: -585.96%
• Return on Assets: -39.96%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 0.55
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $39.17 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.49) per share
• Price / Book: -0.47

Miscellaneous

• Outstanding Shares: 6,220,000
• Free Float: 5,855,000
• Market Cap: $1.45 million
• Optionable: Not Optionable
• Beta: 1.99